# Levosimendan Versus Placebo Before Tricuspid Valve Surgery in Patients With Right Ventricular Dysfunction

> **NCT05233202** · PHASE3 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 230 (estimated)

## Conditions studied

- Patients Referred for an Isolated or a Combined Surgical Correction of Functional Moderate to Severe Tricuspid

## Interventions

- **DRUG:** Levosimendan
- **DRUG:** PLACEBO

## Key facts

- **NCT ID:** NCT05233202
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-23
- **Primary completion:** 2025-01-23
- **Final completion:** 2025-01-23
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2023-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05233202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05233202, "Levosimendan Versus Placebo Before Tricuspid Valve Surgery in Patients With Right Ventricular Dysfunction". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05233202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*